Fundraising Fox
Avery Therapeutics
Tucson, US · Founded 2015 · Arizona corporation · 9 employees on LinkedIn · 1 known investors
Find your way into Avery Therapeutics
Sign up to see every warm intro you have to Avery Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Avery Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Avery Therapeutics is a biotechnology company focused on developing immunomodulatory biologic therapeutics. It is led by an executive team and supported by a board of directors and a scientific and medical advisory board.
Founders & leadership
Avery Therapeutics was founded in 2015 by Jennifer Koevary, Steven Goldman, and Jordan Lancaster.
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$9M disclosed across 2 of 3 rounds · 2017–2026
▶$8.5MraisedSep 2026 · 23 investors · BiotechnologyRule 506(b)
- Jordan LancasterExecutive Officer, Director
- Lawrence MehrenDirector
- Emile NuwaysirDirector
- Steven GoldmanExecutive Officer
- Offering amount
- $15.4M
- Amount sold
- $8.5M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedJun 2017 · 16 investors · Other TechnologyRule 506(b)
- Jennifer KoevaryExecutive Officer
- Steven GoldmanExecutive Officer
- Jordan LancasterExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $500K
- Minimum investment
- $25K
- First sale
- May 2017
- Incorporated
- Corporation, Arizona, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Avery Therapeutics.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $484K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Avery Therapeutics do?
- Avery Therapeutics is a biotechnology company focused on developing immunomodulatory biologic therapeutics. It is led by an executive team and supported by a board of directors and a scientific and medical advisory board.
- Who founded Avery Therapeutics?
- Avery Therapeutics was founded by Jennifer Koevary, Steven Goldman, Jordan Lancaster in 2015.
- Who are Avery Therapeutics's investors?
- Avery Therapeutics's investors include Service Provider Capital.
- How much funding has Avery Therapeutics raised?
- Avery Therapeutics has disclosed $9M raised across 2 of its 3 known rounds.
- Where is Avery Therapeutics headquartered?
- Avery Therapeutics is headquartered in Tucson, US.